Application | Comment | Organism |
---|---|---|
medicine | wild-type p53-expressing LNCaP human prostate cancer cells are more sensitive to cotreatment with selenomethionine and methionine gamma-lyase than p53-null PC3 human prostate cancer cells. Selenomethionine and and methionine gamma-lyase co-treatment significantly increases levels of superoxide and apoptosis in LNCaP cells. Cotreatment selenomethionine and methionine gamma-lyase results in increased levels of phosphorylated p53, total p53, Bax, and p21Waf1 proteins. LNCaP cells treated with selenomethionine and methionine gamma-lyase also show p53 translocation to mitochondria, decreased mitochondrial membrane potential, cytochrome c release into the cytosol, and activation of caspase 9. The effects selenomethionine and methionine gamma-lyase are suppressed by pre-treatment with a synthetic superoxide dismutase mimic or by knockdown of p53 via RNA interference | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
LNCaP cell | prostate cancer cell | Homo sapiens | - |
PC-3 cell | - |
Homo sapiens | - |
prostate | - |
Homo sapiens | - |